Age is just a number: Treatment considerations for endometrial cancer in older women
Disease characteristics and challenges
Endometrial cancer commonly occurs in women aged 55-65 (median age at diagnosis 64 years). Older patients are more likely to have high malignancy, deep myometrial invasion, and advanced disease, requiring adjuvant therapy and facing a high risk of recurrence.
Comorbidities: Approximately 25% of older patients have chronic diseases such as arthritis, cardiovascular disease, and diabetes; 34% of patients ≥70 years of age experience frailty.
Treatment disparities: Older patients are less likely to receive complete staging surgery or standard adjuvant therapy, impacting survival rates, but this is often due to their health status not being of their own volition.
Core of Treatment Decision-Making: Comprehensive Geriatric Assessment (GA)
The International Society for Geriatric Oncology (SIOG) and ASCO recommend replacing simple age assessment with a multidimensional GA, covering:
Functional status, comorbidities, cognitive and psychological status
Social support, nutritional status
Predictive tools for chemotherapy toxicity (such as CARG-TT)
Clinical Tools: ASCO provides a simplified version of the GA scale for easy outpatient use.
Treatment Strategy Adjustments
1. Surgical Treatment
Standard Protocol: Total hysterectomy + bilateral salpingo-oophorectomy + lymph node assessment, but elderly patients have a higher risk of postoperative complications (intestinal obstruction, pneumonia, etc.).
Minimally Invasive Surgery Preferred: Reduces bleeding and shortens hospital stay, but requires assessment of uterine size and disease extent.
Alternatives: Radiotherapy or hormone therapy can be considered for patients unsuitable for surgery (NCCN guidelines recommend).
2. Adjuvant Radiotherapy
Technological Advances: Intensity-modulated radiotherapy (IMRT) reduces pelvic side effects and is suitable for frail patients.
Short-Term Treatment Options: Vaginal brachytherapy is suitable for patients with insufficient social support or those who have previously received pelvic radiotherapy.
Risk Management: Elderly patients with osteoporosis need to be monitored for pelvic stress fractures.
3. Systemic Treatment
Chemotherapy: Carboplatin + paclitaxel is the standard regimen. Completion rates in elderly patients are comparable to those in younger patients, but the risk of peripheral neuropathy is higher (36% vs 20%).
Countermeasures: Ice application to extremities, dosage adjustment, growth factor support.
Immunotherapy:
dMMR/MSI-H tumors: PD-1 inhibitors (such as dostarlimab) are effective as monotherapy.
Combination chemotherapy (such as pembrolizumab + chemotherapy) is used for advanced recurrent cancer, but data on immune-related side effects in elderly populations are limited.
Long-term follow-up and survival care
Cardiovascular risk: Comorbidities such as obesity, diabetes, and hypertension require continuous management.
Treatment sequelae:
Gastrointestinal symptoms (constipation, incontinence) may persist for 5 years.
Urinary system problems (infections, chronic kidney disease) are associated with chemotherapy and radiotherapy.
Molecular subtyping prospective: The PORTEC4a and RAINBO trials are exploring personalized adjuvant therapy based on molecular characteristics.
Key Recommendations:
All elderly patients should undergo frailty assessment (GA) to identify potential vulnerabilities and adjust treatment accordingly.
Multidisciplinary collaboration: Integrate chronic disease management, prehabilitation, and social support.
Avoid inadequate treatment: Age should not be a limiting factor; a balance must be struck between tumor biology and the patient's functional status.
"Frailty assessment is a better predictor of treatment tolerance than actual age, helping us achieve a balance between treatment efficacy and quality of life." —MSK Team
Source: ASCO Guidelines, NCCN Uterine Cancer Guidelines (March 2024 Edition)
Source: https://ascopost.com/issues/january-25-2025/age-is-just-a-number-treatment-considerations-for-endometrial-cancer-in-older-women/